高Khorana评分门诊癌症患者的一级血栓预防:系统综述与荟萃分析
该系统综述与荟萃分析纳入6项随机对照试验共4626例门诊癌症患者,评估Khorana评分中高危(≥2分)患者血栓预防的疗效。结果显示DOAC或低分子肝素显著降低VTE风险,中高危、中危和高危患者的RR分别为0.51、0.58和0.45,NNT分别为25、34和17;大出血和全因死亡无显著差异。
要点
- Khorana评分≥2分的门诊癌症患者,血栓预防显著降低VTE风险。
- 高危患者NNT为17,中危患者NNT为34,高危获益更大。
- 大出血和全因死亡无显著增加,但需注意大出血的NNH数据。
核心结论
- 血栓预防有效降低Khorana评分中高危门诊癌症患者的VTE风险,中危患者NNT为高危患者的两倍。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL,纳入6项随机对照试验共4626例门诊癌症患者。
主要发现
- 血栓预防显著降低中高危患者VTE风险(RR 0.51,95%CI 0.34-0.67),中危患者RR 0.58(95%CI 0.36-0.83),高危患者RR 0.45(95%CI 0.28-0.67)。
- 中高危、中危和高危患者的NNT分别为25、34和17。
- 大出血无显著差异(RR 1.06,95%CI 0.69-1.67),全因死亡无显著差异(RR 0.90,95%CI 0.82-1.01)。
- 中高危、中危和高危患者大出血的NNH分别为1000、-500和334;DOAC研究总体NNH为100,LMWH研究为-500。
关键数值与推荐
- Khorana评分中高危定义为≥2分,中危为2分,高危为≥3分。
- 血栓预防药物包括直接口服抗凝药(DOAC)或低分子肝素(LMWH)。
临床怎么用
- 对Khorana评分≥2分拟开始化疗的门诊癌症患者,可考虑DOAC或LMWH进行一级血栓预防。
- 高危患者(≥3分)血栓预防的绝对获益更大,中危患者需权衡获益与出血风险。
局限性
- 原文未报告纳入研究的偏倚风险、异质性及具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Guidelines suggest thromboprophylaxis for ambulatory cancer patients starting chemotherapy with an intermediate to high risk of venous thromboembolism (VTE) according to Khorana score. Data on thromboprophylaxis efficacy in different Khorana score risk groups remain ambiguous. We sought to evaluate thromboprophylaxis in patients with an intermediate- to high-risk (≥2 points) Khorana score and an intermediate-risk score (2 points) or high-risk score (≥3 points) separately. MEDLINE, Embase, and CENTRAL were searched for randomized controlled trials (RCTs) comparing thromboprophylaxis with placebo or standard care in ambulatory cancer patients. Outcomes were VTE, major bleeding, and all-cause mortality. Relative risks (RRs) were calculated in a profile-likelihood random-effects model. Six RCTs were identified, involving 4626 cancer patients. Thromboprophylaxis with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH) significantly reduced VTE risk in intermediate- to high-risk (RR, 0.51; 95% confidence interval [CI], 0.34-0.67), intermediate-risk (RR, 0.58; 95% CI, 0.36-0.83), and high-risk patients (RR, 0.45; 95% CI, 0.28-0.67); the numbers needed to treat (NNTs) were 25 (intermediate to high risk), 34 (intermediate risk), and 17 (high risk), respectively. There was no significant difference in major bleeding (RR, 1.06; 95% CI, 0.69-1.67) or all-cause mortality (RR, 0.90; 95% CI, 0.82-1.01). The numbers needed to harm (NNHs) for major bleeding in intermediate- to high-risk, intermediate-risk, and high-risk patients were 1000, -500, and 334, respectively. The overall NNH was lower in DOAC studies (100) versus LMWH studies (-500). These findings indicate thromboprophylaxis effectively reduces the risk of VTE in patients with an intermediate- to high-risk Khorana score, although the NNT is twice as high for intermediate-risk patients compared with high-risk patients.
引用
- Bosch FTM, Mulder FI, Kamphuisen PW, et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv. 2020. PMID: 33104795. doi:10.1182/bloodadvances.2020003115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。